4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
Granted 15 Apr 2014 · 2 office actions
Current assignee: Achillion Pharmaceuticals · originally AstraZeneca
Law firm: Law firm · Log in to unlock
Attorney: Attorney · Log in to unlock
Inventors: Suoming Zhang, Atul Agarwal, Cuixian Liu, Godwin Pais +7 · Examiner: Cecilia J Tsang · AU 1654 · TC 1600
Life of the application
13 dated eventsAbstract
The invention provides 4-amino-4-oxobutanoyl peptides and cyclic analogues thereof of Formula I [structure] and the pharmaceutically salts thereof. The variables are defined herein. Certain compounds of Formula I are useful as antiviral agents. 4-amino-4-oxobutanoyl peptide cyclic analogues as disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide cyclic analogues and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptide cyclic analogue as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptide cyclic analogue and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in patients.
Claims as granted
26 claimsLog in to read the claims of this application.
Log in to unlockClassifications
4 codes- A01N37/18
Claim changes
SoonSee which claims were amended, added or cancelled during examination, with every added and removed word marked.
The published claims of this application are not paired with the granted ones in what we hold.
File wrapper
See the full prosecution history — every USPTO and applicant action on this file, in order.
Log in to unlockDocuments
Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.
Log in to unlockChain of title
No assignments have been recorded for this application yet.